Articles by Amanda Lanier

Dollar arrows pointing upward
Biopharma financings November 2023

Biopharma funding hits $5.65B in November, with 18% increase YTD

Dec. 12, 2023
By Amanda Lanier
In November, the biopharma industry raised $5.65 billion in total financings. While down from $11.6 billion tracked by BioWorld in October, overall financings are tracking ahead of last year. Biopharma funding has maintained an average of $6.1 billion per month in 2023, surpassing the $5.07 billion monthly average throughout 2022.
Read More

Graphite’s nula-cel perseveres as Kamau emerges from stealth

Dec. 8, 2023
By Amanda Lanier
Following a strategic transaction with Graphite Bio Inc., Kamau Therapeutics is emerging from stealth with sickle cell treatment nulabeglogene autogedtemcel (nula-cel). Kamau received an option to acquire all of Graphite’s genome editing assets, including a platform technology that integrates precision DNA repair using homology directed repair and CRISPR/Cas9, as well as the autologous CRISPR/Cas9 gene corrected CD34+ cell product nula-cel, which offers a potential cure for sickle cell disease derived from the patient's cells.
Read More
Dollar arrows pointing upward
Biopharma financings November 2023

Biopharma funding hits $5.65B in November, with 18% increase YTD

Dec. 8, 2023
By Amanda Lanier
In November, the biopharma industry raised $5.65 billion in total financings. While down from $11.6 billion tracked by BioWorld in October, overall financings are tracking ahead of last year. Biopharma funding has maintained an average of $6.1 billion per month in 2023, surpassing the $5.07 billion monthly average throughout 2022.
Read More
Brain, illustrating pain/injury
BioWorld Neurological Diseases Index (BNDI)

Volatility defines neurological disease stocks in 2023

Dec. 4, 2023
By Amanda Lanier
Clinical data disappointments and third-quarte results cast a shadow on the BioWorld Neurological Diseases Index, closing November with an 18.37% year-to-date decline. This marks a slight improvement from its low point in October, down 23.79%, in contrast to the previous year’s upward trend, which it concluded with an 18.24% increase.
Read More
Health professional holding stethoscope with health icons
Biopharma clinical updates October 2023

Clinical trial updates up nearly 5% through October

Nov. 28, 2023
By Amanda Lanier
Clinical trial updates for the period of January to October 2023 saw an increase of 4.6% compared to the same time period last year. Comparatively, clinical data from January to September 2023 was up 1.79% compared to the same period last year.
Read More
Health professional holding stethoscope with health icons
Biopharma clinical updates October 2023

Clinical trial updates up nearly 5% through October

Nov. 22, 2023
By Amanda Lanier
Clinical trial updates for the period of January to October 2023 saw an increase of 4.6% compared to the same time period last year. Comparatively, clinical data from January to September 2023 was up 1.79% compared to the same period last year.
Read More
Illustration of pill being analyzed
BioWorld Drug Developers Index (BDDI)

Blueprint Medicines up on Q3 results amidst broader drug developer decline

Nov. 22, 2023
By Amanda Lanier
BioWorld’s Drug Developers Index continued to fall in October, down 31.4% for the year, compared to September when it ended down 22.8%. Among the 30 stocks tracked, only five saw gains, with the remaining 25 experiencing declines, aligning with the year’s overall trend through Nov. 16. In March, the index experienced a 12.56% drop, stayed around negative 12% through July, and has faced steady declines since.
Read More